NLS Acquisition

By combining Pelago Bioscience's biology-focused capabilities with RG Discovery's chemistry expertise, the enlarged platform will enable drug discovery teams to accelerate decision-making, streamline workflows, and advance programs more efficiently from hit identification through lead optimization, the company states.

Johnson & Johnson has announced it has entered into a definitive agreement to acquire Firefly Bio, biotech company advancing its Firelink degrader antibody conjugate (DAC) platform, for USD 1 billion in cash.

French pharma company Servier has entered into an agreement to acquire the muscular dystrophy business of US Edgewise Therapeutics for up to USD 2.65 billion, including upfront payment of USD 1.55 billion as well as up to USD1.1 billion in regulatory and commercial milestone payments.

The acquisition adds expertise and a next generation gene therapy platform to LEO Pharma’s pipeline through Replay’s high‑payload herpes simplex virus (HSV) delivery vector.

Under the terms of the Transaction, Chiesi will commence a tender offer to acquire all outstanding shares of KalVista for USD 27.00 per share in cash. The total value implied by the transaction at closing is approximately USD 1.9 billion.

Belgian company UCB has announced signing of a definitive agreement under which it would acquire Candid Therapeutics, a privately held clinical-stage biotechnology company redefining the treatment of autoimmune and inflammatory diseases through novel T-cell engagers (TCEs).